The results of the J-PAD study, recently presented at the American Heart Association (AHA) Annual Meeting in New Orleans in November 2008, show that low-dose aspirin in primary prevention significantly reduces mortality from cardiovascular events in type 2 diabetes without increasing the risk of hemorrhagic events. The J-APD study is the world’s first randomized, controlled study of low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes, and the first aspirin primary prevention study to focus on an Asian population. 2,539 patients aged 30 to 85 years with type 2 diabetes from 163 medical centers in Japan participated in the study and were followed up for 4.37 years. The results showed that aspirin significantly reduced mortality from cardiovascular events in patients with type 2 diabetes. The use of aspirin apparently weakened the “power” of diseases such as myocardial infarction and stroke, allowing diabetic patients to withstand these diseases without losing their lives. According to the professor, “thrombosis is the direct cause of fatal myocardial infarction and stroke, and 60-80% of diabetic patients eventually die from cardiovascular and cerebrovascular events. The results of this trial further demonstrate the importance of aspirin in patients with diabetes as an effective, safe and inexpensive way to prevent thrombosis in the large number of diabetic patients in China. In fact, several authoritative diabetes guidelines recommend the routine use of aspirin in patients with type 2 diabetes over the age of 40. aspirin is also recommended in patients with type 1 diabetes and in patients with type 2 diabetes younger than 40 years of age who have risk factors for cardiovascular disease.” The results of the JPAD study have increased confidence in the safety of aspirin, and the trial’s principal investigator, Professor Ogawa, said, “The JPAD study results show that low-dose aspirin has a good safety profile in the Asian diabetic population as well, and that aspirin is safe and effective in preventing cardiovascular death in patients with diabetes. ” The treatment of diabetes has entered the era of prevention and control of complications, and reducing the risk of cardiovascular death in diabetic patients is a top priority in the treatment and management of diabetes!